<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616291</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000579579</org_study_id>
    <secondary_id>P50CA058204</secondary_id>
    <secondary_id>BCM-H-17274</secondary_id>
    <secondary_id>BCM-SPORE-11-01-30-14</secondary_id>
    <nct_id>NCT00616291</nct_id>
    <nct_alias>NCT00711334</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer</brief_title>
  <official_title>Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an effective immune response&#xD;
      to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of a peptide vaccine in treating&#xD;
      patients with metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the safety and tolerance of NY-ESO-1/LAGE-1 class-I and class-II vaccine&#xD;
           administered subcutaneously in patients with androgen-independent metastatic prostate&#xD;
           cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the response induced by immunotherapy with a combined class-I and class-II&#xD;
           NY-ESO-1/LAGE-1 vaccine to responses obtained to either class I or class II peptides&#xD;
           alone.&#xD;
&#xD;
        -  Evaluate whether the inclusion of class-II epitopes in a peptide vaccine will result in&#xD;
           a better antitumor immune response than class-I epitopes alone.&#xD;
&#xD;
        -  Determine antitumor activity by antigen response assays including cytokine elaboration,&#xD;
           changes in frequency of peripheral T cells that recognize tumor, and intra/peritumoral&#xD;
           cellular infiltrates and cytokine expression in responding and nonresponding metastasis.&#xD;
&#xD;
      OUTLINE: Patients receive NY-ESO-1/LAGE-1 peptide vaccine subcutaneously every other week for&#xD;
      12 weeks in the absence of disease progression or unacceptable toxicity. The initial cohorts&#xD;
      of patients are treated with one course of either MHC Class I-binding or MHC Class II-binding&#xD;
      peptides. If these Class I or Class II binding peptides are safe individually, subsequent&#xD;
      cohorts of patients with appropriate HLA type receive both types of peptides in combination.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological response</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MHC Class I binding peptide at 1000 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MHC Class II binding peptide at 1000 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination MHC Class I and II binding peptide at 1000 mcg each</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine</intervention_name>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer with evidence of progressive disease despite&#xD;
             hormonal therapy (i.e., hormone-refractory prostate cancer)&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Progressive disease defined by any of the following:&#xD;
&#xD;
                    -  New bone lesion on bone scan&#xD;
&#xD;
                    -  Progression of nodal or soft tissue as evidenced by standard radiographic&#xD;
                       methods, i.e., CT scan or MRI&#xD;
&#xD;
                    -  A 50% increase in PSA level from the nadir PSA level confirmed twice and&#xD;
                       measured at least 2 weeks apart, with stable and measurable disease&#xD;
&#xD;
          -  Castrate serum levels of testosterone &lt; 50 ng/dL&#xD;
&#xD;
          -  If patient was receiving anti-androgen therapy, in addition to luteinizing&#xD;
             hormone-releasing hormone (LHRH) agonist therapy, the evidence of progressive disease&#xD;
             should persist after a trial of anti-androgen withdrawal&#xD;
&#xD;
               -  Treatment with LHRH agonist to maintain androgen ablation must continue&#xD;
                  throughout this trial&#xD;
&#xD;
          -  Baseline PSA ≥ 10 ng/mL&#xD;
&#xD;
          -  All patients with androgen-independent prostate cancer and matched HLA typing are&#xD;
             eligible for vaccination regardless of initial NY-ESO-1 expression status&#xD;
&#xD;
               -  Patients must be typed for HLA-DR4, DR13, DP4, or HLA-A2 haplotypes&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 mg/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  SGPT ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Serum creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Wiling to be followed at Baylor College of Medicine&#xD;
&#xD;
          -  No serious intercurrent medical illness&#xD;
&#xD;
          -  No history of primary or secondary immunodeficiency&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No known hepatitis B surface antigen, hepatitis C, or HIV antibody positivity&#xD;
&#xD;
          -  No history of cardiac arrhythmia or ischemic heart disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior immunotherapy (including anti-androgen therapy) and&#xD;
             recovered&#xD;
&#xD;
          -  More than 28 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs such as systemic corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa G. Hayes, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Veterans Affairs Medical Center - Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dan L. Duncan Cancer Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>November 5, 2012</last_update_submitted>
  <last_update_submitted_qc>November 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Teresa Hayes</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

